Gain-of-function (GOF) mutations in PCSK9 result in familial hypercholesterolemia (FH), whereas loss-of-function (LOF) mutations are associated with life-long reductions in plasma LDL-C and significant protection from cardiovascular heart disease (4, –, 6). This evidence concerns the gene PCSK9 and familial hyperaldosteronism.